FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular, to a strain of hybrid cultured animal cells Mus musculus 2E1B5. Hybrid clone of 2E1B5 cells was produced by fusion of mouse myeloma cells of the Sp2/0-Ag-14 line with splenocytes of mice of the Balb/c line, immunised intramuscularly with the recombinant receptor-biniding domain of protein S of the SARS-CoV-2 virus. Hybridoma 2E1B5 synthesises an IgG1-class monoclonal antibody specifically interacting with the recombinant receptor-binding domain of protein S of the SARS-CoV-2 virus, full-length S protein of the SARS-CoV-2 virus, and inactivated SARS-CoV-2 virus. The antibody exhibits virus-neutralising activity and is capable of neutralising the SARS-CoV-2 virus in vitro. The resulting antibody can be used in diagnostic studies in order to detect an antigen and specific antiviral antibodies and to create medicinal products against the SARS-CoV-2 virus.
EFFECT: invention expands the range of means for producing monoclonal antibodies against protein S of the SARS-CoV-2 virus.
1 cl, 1 dwg, 1 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
STRAIN OF HYBRID ANIMAL CELLS Mus MUSCULUS 1F1 - PRODUCER OF A MONOCLONAL ANTIBODY AGAINST THE NUCLEOCAPSID PROTEIN N OF THE SARS-CoV-2 VIRUS | 2021 |
|
RU2769817C1 |
MONOCLONAL ANTIBODY TO RDB FRAGMENT IN COMPOSITION OF SARS-COV-2 S PROTEIN | 2020 |
|
RU2744274C1 |
HUMANIZED MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO RBD S OF THE PROTEIN OF THE SARS-COV-2 VIRUS, AGENT AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS-COV-2 VIRUS | 2021 |
|
RU2765731C1 |
MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY | 2021 |
|
RU2769223C1 |
THE STRAIN OF HYBRID CULTURED HOMO SAPIENS/Mus MUSCULUS CELLS Hu-C6D7-RBD IS A PRODUCER OF HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO THE RBD DOMAIN S OF THE SARS-CoV-2 VIRUS PROTEIN | 2022 |
|
RU2788359C1 |
POLYPEPTIDE WITH ANTI-SARS-COV-2 ACTIVITY AND PROLONGED CIRCULATION TIME IN BLOOD FLOW | 2023 |
|
RU2822355C1 |
SINGLE-DOMAIN LLAMA ANTIBODY H5 AND ITS DERIVATIVE H5-Fc SPECIFICALLY BINDING THE RBD DOMAIN OF THE S-PROTEIN OF THE SARS-CoV-2 VIRUS POSSESSING VIRUS-NEUTRALIZING ACTIVITY | 2022 |
|
RU2793967C1 |
MONOCLONAL ANTIBODY IC1 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817696C1 |
BROADLY NEUTRALIZING ANTIBODY AGAINST SARS-CoV-2 | 2022 |
|
RU2810476C1 |
MONOCLONAL ANTIBODY IC2 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817697C1 |
Authors
Dates
2022-04-29—Published
2021-02-02—Filed